Recent

% | $
Quotes you view appear here for quick access.

Spectrum Pharmaceuticals, Inc. Message Board

  • antisense_science antisense_science Jan 31, 2013 11:12 AM Flag

    Allergan opted out because of MAP deal.

    Allergan exited because of MAP deal, should Spectrum get an approval the milestone payments would adversely impact the bloated balance sheet. MAP is costing Allergan 900M + fees. Map balance sheet brings in less than $100M to Allergan. So people like Adam who read too much into the reasons for Allergan to opt out at this stage need to stop and think, there could be more than a reason for Allergan to exit A. But he is busy putting his own spin on the news today.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Adam has ZERO CREDIBILITY. can anyone be negative for every single thing ? he has his motives. maybe Jim cramer's hedge fund has heavily shorted SPPI and Adam is just helping him.
      unfortunately , unethical things happen. Unfortunately retail are weak hands...one day of bad press and declining stock price, they get scared and sell...and shorts cover. making a profit . this is how such a scheme works.

    • I always wondered why on earth is Allergan branching out into cancer drugs. Looking at the Yahoo Profile I pasted below you would never have thought they would buy into a cancer drug. Even though they are involved in urologicals, they would have to set-up a separate sales team to sell it. From outside looking in you would scratch your head on why Allergan made this deal. I guess someone inside the organization was also scratching their heads. Here’s the Yahoo Profile:

      “Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes specialty pharmaceutical, biologics, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for chronic dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and over-the-counter skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; obesity intervention products comprising the Lap-Band System and the Orbera Intragastric Balloon System; and facial aesthetics products. The company sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, and medical practitioners. It focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, bariatric surgeons, urologists, and general practitioners.”

      • 1 Reply to antihama2001
      • SPPI get it back because they know that they can make it work and have the sales force to carry it through.....Allergan specializes in MAP which is medical devices apparatus so they are not into cancer research and prevention etc. it's just not their thing.....they have no idea how to do these trials so that why SPPI is taking over.....if SPPI does not think there is a way they can do the trial better and get better results than the other 2 trials, they would not pull the trigger....

        Sentiment: Strong Buy

    • What is MAP?

    • institutions dont listen to adam. he writes what they tell him to write.
      sppi retail longs disregard adam fraudstein. he's the boy who cried wolf. he is clueless.
      that leaves only retail shorts to rally around adam fraudstein published fictional quips bashing sppi.
      and retail has zero influence in the sppi price action.
      so let the chithead tweet whatever he wantz...............

 
SPPI
6.27+0.05(+0.80%)May 29 4:00 PMEDT